Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) posted its quarterly earnings data on Thursday. Here are the key takeaways from Halozyme Therapeutics’ conference call:Get Halozyme Therapeutics alerts:Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $103.30. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday. Featured StoriesReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.